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Objectives To assess whether human papillomavirus (HPV) testing is a safe enough approach to
warrant extension of the screening intervals of baseline Papanicolaou (Pap)2/HPV2 women in
low-income settings.
Methods Of the .1000 women prospectively followed up as part of the Latin American Screening
(LAMS) Study in Sa˜o Paulo, Campinas, Porto Alegre) and Buenos Aires, 470 women with both
baseline cytology and Hybrid Capture 2 (HC2) results available were included in this analysis.
These baseline Pap-negative and HC22 or HC2þ women were controlled at six-month intervals
with colposcopy, HC2 and Pap to assess the cumulative risk of incident Pap smear abnormalities
and their predictive factors.
Results Of the 470 women, 324 (68.9%) were high-risk HPV (hrHPV) positive and 146 (31.1%)
were negative. Having two or more lifetime sex partners (odds ratio [OR] ¼ 2.63; 95% CI 1.70–
3.51) and women using hormonal contraception (OR ¼ 2.21; 95% CI 1.40–3.51) were at
increased risk for baseline hrHPV infection. Baseline hrHPVþ women had a significantly increased
risk of incident abnormal Pap smears during the follow-up. Survival curves deviate from each other
starting at month 24 onwards, when hrHPVþ women start rapidly accumulating incident Pap
smear abnormalities, including atypical squamous cells (ASC) or worse (log-rank; P, 0.001), low-
grade squamous intraepithelial lesions (LSIL) or worse (P, 0.001) and high-grade squamous
intraepithelial lesions (HSIL) (P ¼ 0.03). Among the baseline hrHPV2 women, the acquisition of
incident hrHPV during the follow-up period significantly increased the risk of incident cytological
abnormalities (hazard ratio ¼ 3.5; 95% CI 1.1–11.7).
Conclusion These data implicate that HPV testing for hrHPV types might be a safe enough approach
to warrant extension of the screening interval of hrHPV2/Pap2women even in low-resource settings.
Although some women will inevitably contract hrHPV, the process to develop HSIL will be long enough
to enable their detection at the next screening round (e.g. after three years).
INTRODUCTION
B
ased on firm documentation of efficacy and feasi-
bility, the combined use of cervical cytology and
high-risk human papillomavirus (hrHPV) testing
has been proposed as an optional approach in screening of
cervical cancer in the USA.1–5 One of the advantages of
this approach includes the possibility of lengthening the
screening intervals to three years or more, because women
with a negative HPV test and normal cytology are at an
extremely low risk of developing cervical cancer in the
next three to five years.3
A series of large cohort studies to provide evidence on the
safety of screening HPV-negative women at three-year inter-
vals are ongoing, using various study designs.6 Until to date,
the bulk of the current evidence favouring the extended
screening intervals is derived from developed countries
with effective screening programmes.7 In low-resource
settings, the main efforts have been focused on finding the
ways how to overcome the difficulties in cervical cytology,
by running cross-sectional studies to compare optional
screening tools, e.g. visual inspection with acetic acid
(VIA)/lugol iodine (VILI) and cervicography.8,9 Longitudinal
cohort studies capable of confirming the safety of extended
screening intervals, based on hrHPV testing or any other
screening techniques, are currently not available in the low-
resource settings.
In a recent meta-analysis of the prospective studies on
HPV tests as a predictor of cervical disease, it has been
shown that the predictive value of HPV tests is largely
dependent on the disease prevalence in each setting,
which precludes extrapolation of the results to populations
with different disease burden e.g. in different regions of
Latin America.7 In Brazil and Argentina (the two largest
Latin American countries), screening for cervical cancer is
based on cervical cytology but flawed due to several
reasons. Most notably, these failures are a consequence of
the lack of structured network of public health services,
 LAMS (Latin American Screening) Study, funded by European Commission,
INCO-DEV Contract # ICA4-CT-2001-10013.
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the extent of these countries’ territories and the geographic
dispersion of their populations.10,11 For these reasons, Brazil
and Argentina are fertile grounds for studies testing optional
measures for cervical cancer screening.
This prompted us to design the Latin American Screening
Study (LAMS Study), a multicentre collaborative trial evalu-
ating eight different screening techniques for cervical cancer
in different regions of Brazil and Argentina.12 A cohort of
over 12,000 women was enrolled from five different
regions, the study design, baseline data and tentative
results of hrHPV testing and VIA/VILI being reported.13,14
Based on the completion of the prospective follow-up of
over 1000 of these women,13 the present study reports the
acquisition of cytological abnormalities among baseline
hrHPV-positive and hrHPV-negative women, derived from
this low income, relatively unassisted and previously incom-
pletely studied Latin American population. The main aim
was to assess, whether hrHPV testing is a safe enough
approach to warrant extension of the screening intervals
of those women who test Papanicolaou (Pap)- and
hrHPV-negative at baseline. If applicable, such an extension
would be of great interest to health authorities planning new
measures for cervical cancer prevention in a setting with
limited health-care resources.
SUBJECTS ANDMETHODS
Study design
LAMS study is a multicentric study, sponsored by the
European Commission through its INCO-DEV programme
(ICA4-CT2001-10013). In this study, consecutive women
from the cities of Campinas, Sa˜o Paulo and Porto Alegre
(Brazil) as well as Buenos Aires (Argentina) were recruited
to undergo gynaecological examination and testing with
conventional Pap smear, VIA or VILI, cervicography and
screening colposcopy. Women were sampled for hrHPV
testing by Hybrid Capture 2 (HC2). All centres performed
conventional Pap smear, HC2 and VIA, whereas Porto
Alegre performed VILI, Buenos Aires did screening colpo-
scopy and Campinas did cervicography.13,14 The study pro-
tocol has been approved by the local Ethics Committees of
all participating clinics. All enrolled women gave their agree-
ment to participate by signing the informed consent forms,
written in their native language.
Study centres and their demographics
The study design and features of the clinical centres as well
as the demographics of their regions were described in detail
recently.13,14 In brief, Campinas and Sa˜o Paulo are two large
south-western Brazilian cities, located only 100 km apart,
with equivalent standards of living. Cervical cancer is the
fourth major cause of cancer death among women, account-
ing for 3.3% of all female deaths due to cancer.11 The third
Brazilian partner is from Porto Alegre, located south of the
country. This region offers the best quality of life in Brazil,
and cervical cancer is the sixth major cause of cancer
death, accounting for 6.1% of all female deaths due to
cancer.11 The Argentine partner is from Buenos Aires. The
country has an overall cervical cancer mortality rate of
7.6/100,000 women,10 but most of the national statistics
pertain to Buenos Aires city only.
Enrolment and eligibility of thewomen
Slightly different protocols were used to recruit the women
in different clinics. In Sa˜o Paulo, Porto Alegre and Buenos
Aires, eligible women were informed of the study protocol
by their local health units, inviting them to participate. In
Campinas, in addition to this same approach, students and
employees of the University Hospital were invited through
an open announcement, widely distributed in the university
facilities.
Women were considered eligible, if they met all of the fol-
lowing criteria: (1) age between 15 and 60 years; (2) no pre-
vious surgical procedure of the cervix or corpus; (3) had no
history of abnormal Pap test in the past year; (4) free of
known current genital condyloma (external or in the
cervix), cervical intraepithelial neoplasia (CIN) or cervical
carcinoma; (5) had no sexual intercourse during the three
days prior to the examination; (6) did not have any con-
firmed or clinically suspect immunosuppression (HIV, or
other conditions that might compromise the immune
system).
Diagnostic setting
After signing the informed consent, women undertook a
questionnaire addressing clinical and epidemiological risk
factors of HPV, CIN and cervical cancer. All women under-
went thorough pelvic examination in this sequence: (1) col-
lection of the Pap smear, (2) collection of HC2 sample and
(3) VIA. In Porto Alegre, most women underwent VILI
shortly after VIA. All women, who had at least one of
these examinations abnormal, were referred for colposcopic
examination. In Buenos Aires and Campinas, women
underwent screening colposcopy even when their exams
were negative. Abnormal colposcopy prompted punch biop-
sies of the cervix, and women with high-grade squamous
intraepithelial lesions (HSIL) were treated by conization.
Women had their second visit scheduled for one and a
half months (average 45 days), to become informed about
their exam/biopsy results and to be allotted to either (1)
the treatment- or (2) the follow-up group. Treatment was
offered to all women who had high-grade lesion (CIN2–3)
confirmed in the cervical biopsy. Altogether, 32 cases of
invasive cervical cancer were diagnosed during the recruit-
ment phase and all were treated according to each insti-
tution’s regular protocols.
Follow-up
A total cohort of 1011 women completed at least one
follow-up visit. In the present study, however, we analysed
the follow-up data derived from a cohort of 689 women,
who attended at least one follow-up visit and who had
both baseline cytology and HC2 results available. This
group was further reduced to 470, because 219 women
had ASC (atypical squamous cells) or worse in their baseline
cytology or CIN1 or worse in their baseline cervical biopsy.
Women with these conditions were treated according to
the study protocol as described elsewhere.14 Therefore, the
study sample in the present study consists of 470 women
with negative baseline cytology and normal colposcopy
and/or normal biopsies, who attended at least one follow-up
visit.
The follow-up workup for women considered ‘normal’
after baseline assessment was similar in all study centres,
with follow-up visits being scheduled at six-month intervals.
The study protocol determined that women should be
98 Derchain et al.
Journal of Medical Screening 2008 Volume 15 Number 2 www.jmedscreen.com
re-examined four times (optimal moments should have
been 6, 12, 18 ad 24 months; see below). At each follow-up
visit, women responded to a brief questionnaire addressing
any relevant gynaecological events and epidemiological fea-
tures changed since the previous control (e.g. sexual part-
ners, smoking). The total follow-up time encompassed in
this report approaches 50 months, but the bulk of the data
covers approximately 36 months (median follow-up
time ¼ 24.4 months; 90% central range ¼ 6.8–32.2
months) (Figure 1).
Difficulties with follow-up
Longitudinal studies in low-income settings are known to
be affected by severe loss-to-follow-up phenomena. The
researchers tried to keep consultations as close as possible
to these target points, but several factors made it impossible
to maintain follow-up on schedule. First and foremost, diffi-
culties to contact women that had missed one of the
follow-up consultations led to a delay on several scheduled
consultations. Most women in the present study belong to
low-income populations, and therefore home addresses
and telephone contact numbers fluctuate over time.
Table 1 shows the distribution of women at each ‘target’
follow-up point according to the actual time point at
which they attended consultations. The researchers tried to
circumvent the patients’ difficulties to attend consultations
by offering transportation to the clinics and by re-scheduling
consultations at the patients’ conveniences. Follow-up
therefore ranged from 6 to 49 months, although the bulk
of data covers 36 months.
Cervical cytology (pap smear)
Conventional Pap smears were taken using the Ayre spatula
and endocervical brush, fixed in 95% ethanol and stained by
the modified Pap method. Final cytological diagnoses were
issued by using the Bethesda System15 and were classified
as normal/inflammatory, ASC, atypical glandular cells,
LSIL, HSIL or cancer.
Hybrid capture 2
The specimens for HC2 were tested with probe B for hrHPV
types: HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and
68)16 and the tests were classified positive at the relative light
unit/positive control (RLU/CO) ratio of 1 pg/mL or greater.
These RLU/CO ratios provide a semi-quantitative estimate of
the amount of HPV DNA in the specimens, i.e. the viral load
in the sample. Storage of specimens and reagents, as well as
exams processing, were carried out in manufacturer-certified
laboratories, under the responsibility of the investigators, fol-
lowing the manufacturer’s instructions (Digene Diagnostics
Inc., USA). Sa˜o Paulo and Buenos Aires processed their
own HC2 samples in-house, whereas Campinas and Porto
Alegre had their HC2 specimens processed at Campinas
University hospital laboratory.
Statistical analysis
All statistical calculations were performed with the
R-environment for statistical computing,17and 95% CI
were calculated where appropriate. Intra-class correlation
coefficients were calculated to assess the agreement (i.e.
re-incidence or repetition of Pap abnormalities) in pairs of
cytological assessment rounds. A logistic regression model
was used to analyse the power of epidemiological (and clini-
cal) variables as predictors of the baseline hrHPV status, cal-
culating odds ratio (OR) and 95% CI. Multivariate survival
(Cox proportional hazards) analysis was used to calculate
hazard ratios (HR) for incident Pap smear abnormalities in
three distinct cohorts: (1) the complete sample; (2) women
with positive baseline hrHPV; (3) women with negative
baseline hrHPV, adjusted for clinical and epidemiological
features as well as their hrHPV status at baseline and
during follow-up. Univariate survival (Kaplan-Meier)
analysis was used to calculate the survival curves (in the
whole cohort) for accumulation of incident HSIL during
the follow-up, separately for baseline hrHPV-positiveFigure 1 Schematic overview of the study design
Table1 Time-related distribution of the women that attended
follow-up visits
Follow-up time periods
(in months)
Number
Min 25% 50% 75% Max of cases
First visit
Target ¼ 6 months
5.4 6.2 6.4 7.6 9.1 267
Second visit
Target ¼ 12
months
11.7 12.2 13.2 15.4 17.5 301
Third visit
Target ¼ 18
months
17.8 18.2 19.0 21.3 23.4 235
Last visit
Target ¼ 24
months
23.9 24.4 26.2 29.5 49.1 301
Complete cohort 5.4 9.8 17.6 24.4 49.1 470
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and -negative women. For cases of ASC or worse and LSIL
or worse, the patients’ status at their last follow-up visit
was considered. This strategy was implemented to avoid cen-
soring cases with transient conditions, such as ASC or LSIL,
which would afterwards develop more severe cytological
abnormalities or simply subside. The curves were compared
using log-rank (Mantel-Cox) statistics.
RESULTS
Table 2 summarizes the predictors of baseline hrHPV status
in multivariate regression analysis. Of the 470 women, 324
(68.9%) were hrHPV positive and 146 (31.1%) were nega-
tive. Having two or more lifetime sex partners (OR ¼ 2.63;
95%CI 1.70–3.51) and women using hormonal contracep-
tion (OR ¼ 2.21; 95%CI 1.40–3.51) were at increased risk
for baseline hrHPV infection. Other implicated risk factors
of hrHPV, e.g. age at first intercourse and smoking habits,
were not significant predictors of baseline hrHPV status in
this cohort.
The vast majority of incident cytological abnormalities
diagnosed during the follow-up were found among
women who tested hrHPV positive at baseline. However,
the prevalence of incident ASC, LSIL and HSIL at three
follow-up time points (6-, 12-, 24-months) did not differ
among hrHPVþ and hrHPV2 women. At six months, 41
women had newly diagnosed abnormal Pap tests, only one
of those being hrHPV2 at baseline. However, most of the
women (191/224) who attended the six-month follow-up
visit had a positive baseline hrHPV test. At 12- and
24-month visits, women with positive baseline hrHPV still
represented the majority among those with incident Pap
smear abnormalities (data not shown).
The actual time points at which women attended the
follow-up consultations are depicted, in quartiles, in
Table 1. The number of cases at each visit ranged from a
minimum of 235 (third visit, planned to target women 18
months after baseline assessment) to a maximum of 301
(reached at the second [12 months] and last [24 months]
visits). Although 470 women attended at least one follow-up
visit, attendance varied as follows: 174 attended one
follow-up visit, 84 attended two, 82 attended three visits
and 130 completed the follow-up programme (data not
shown).
Table 3 depicts the incidence of cytological abnormalities
at each follow-up visit as a function of the Pap results in pre-
vious exams. HSIL was detected in exams collected at the
first, third and last follow-up visits. Women that were
found to have HSIL at one given visit are reported to be
‘missing’ in the next ones; however, they were excluded
from the normal follow-up schedule, treated, and allotted
to another follow-up series, not under the scope of the
present report. The intra-class correlation coefficient (ICCs)
calculated for each pair of follow-up consultations varied
between 0.135 (second versus third visits) and 0.279
(second versus last), revealing that cytological results
agreed (i.e. repetition of cytological abnormalities) the best
considering the 12 months and the final assessment of the
women. However, the clinical relevance of these figures is
questionable: it must be noted that the 12 and 24-month
visits were the most attended (301 women at each) and
the higher ICC for the comparison of these two rounds is
much likely attributable to the fact that more women
attended both these consultations as compared with any of
the other ‘visit X visit’ tabulations.
Figure 2 summarizes the cumulative incidence of new
abnormal Pap smears among baseline hrHPVþ and
hrHPV2 women in univariate (Kaplan-Meier) analysis.
Clearly, baseline hrHPVþ women had a significantly
increased risk of incident abnormal Pap smears during the
follow-up. Survival curves deviate from each other starting
at month 24 onwards, when hrHPVþ women start rapidly
accumulating incident Pap smear abnormalities, including
ASC or worse (log-rank; P, 0.001), LSIL or worse
(P, 0.001) and HSIL (P ¼ 0.03).
The risk estimates for incident Pap smear abnormalities
during a 24-month follow-up period in Cox analysis are
depicted in Table 4. Positive baseline hrHPV status
(HR ¼ 3.4; 95%CI 1.8–6.4) and age at first intercourse
below 18 years (HR ¼ 1.9; 95%CI 1.2–3.0) were the two
significant predictors of incident cytological abnormalities
in the present (whole) cohort. Among the sub-cohort of
baseline hrHPVþ women, none of the recorded epidemiolo-
gical variables were shown to be significant predictors.
Among the baseline hrHPV2 women, the acquisition of
incident hrHPV during the follow-up period proved to
increase the risk of incident cytological abnormalities
(HR ¼ 3.5; 95%CI 1.1–11.7).
Discussion
During the past few years, HPV detection technology has
become standardized and cost-effective, and HPV tests
have recently gained increasing importance as potential
tools in cervical cancer screening.3,6 HPV testing has an
almost 100% negative-predictive value for the absence of
significant cervical lesions when the test is negative. This
has prompted several professional societies, e.g. the
American Cancer Society (ACS) and the American College
of Obstetrics and Gynecology (ACOG) to issue guidelines
recommending a combined use of HPV tests with cytology.
Useful as these guidelines might be in high-resource settings,
it is imperative to realize that these are based on the epide-
miological profile of the populations where HPV testing has
been shown to predict future cervical abnormalities, which
is not necessarily the case in many low-resource
settings.18,19
Table2 Predictors of the baseline hrHPV status in multivariate
analysis
Baseline hrHPV
Characteristic
Positive
(n ¼ 324)
Negative
(n ¼ 146) OR 95% CI
,30 141 (43.5) 57 (39.6) 0.80 (0.23–1.28)
30 183 (56.5) 87 (60.4) Ref.
First intercourse
, 18 years 181 (55.8) 66 (45.2) 1.37 (0.88–2.13)
 18 years 143 (44.2) 80 (54.8) Ref.
Life time partners
 2 234 (72.2) 74 (50.7) 2.63 (1.70–3.51)
1 90 (37.8) 72 (49.3) Ref.
Contraceptive methods
Hormonal 144 (44.6) 42 (28.8) 2.21 (1.40–3.51)
Without 42 (13.0) 17 (11.6) 1.88 (0.97–3.65)
Non-hormonal 137 (42.4) 87 (59.6) Ref.
Smoking
Yes 76 (23.4) 37 (25.3) 0.69 (0.42–1.16)
Past 49 (15.2) 22 (15.1) 0.90 (0.49–1.64)
Never 199 (61.4) 87 (59.6) Ref.
OR, odds ratio; HrHPV, high-risk HPV
Adjusted with logistic regression
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While testing optional screening tools in low-resource set-
tings, our LAMS study provides data that enables tackling
the validity of these ACS and ACOGs guidelines in another
type of environment, where the prevalence of HPV infection
and cervical cancer are dramatically different. Importantly,
several co-factors are needed to make hrHPV infections
capable of producing clinically significant cervical disease
(CIN2–3), and these potential co-factors (e.g. reproductive
factors, sexual behaviour, smoking, nutrition, concomitant
gynaecological infections) are known to differ substantially
among women living in high-and low-resource settings.20,21
Thus, if HPV testing is to be proposed as a suitable screening
tool for these unprivileged conditions, the performance of
this technology needs to be established in prospective
cohort studies conducted under field conditions in these par-
ticular.6,7 This is exactly what the LAMS study has done, and
the data provided in the present study should constitute an
important tool for health policy-makers, while confirming
the significant predictive value of hrHPV test as determinant
of incident Pap smear abnormalities also among these low-
income women (Table 1; Figure 1).
The sample of the present study (n ¼ 470) represents a
selected sub-cohort derived from over 12,000 women exam-
ined at baseline in the LAMS study, of whom over 1000
completed at least one follow-up visit.13 Despite this selec-
tion, this series of patients is consistent with the large cross-
sectional studies, as to the epidemiological risk factors of
cervical disease.6,7 In this sub-cohort, the number of lifetime
partners and hormonal contraception were closely related to
HPV infection, whereas age, age at first intercourse, and
smoking were not (Table 2). This is not unexpected, given
the fact that this subset of the LAMS cohort analysed in
this study was not large enough to give the study a high stat-
istical power to detect minor true differences in these
Table 3 Cytological abnormalities at each follow-up visit according to the results of a previous follow-up cytology
Visit
Second Third Last
Neg. ASC/AGC LSIL HSIL Miss. Neg. ASC/AGC LSIL HSIL Miss. Neg. ASC/AGC LSIL HSIL Miss.
First visit
Negative 145 13 2 0 65 126 8 3 0 89 134 5 2 1 84
ASC/AGC 12 2 1 0 6 10 4 0 0 6 10 3 1 0 7
LSIL 10 4 1 0 4 15 0 1 0 2 13 3 1 0 2
HSIL 0 0 0 0 1 0 0 0 0 1 0 0 0 0 1
Missing 102 6 2 0 93 62 2 2 0 137 116 9 2 1 75
ICC ¼ 0.193 ICC ¼ 0.166 ICC ¼ 0.168
Second visit
Negative – – – – – 157 11 2 0 99 159 11 0 0 98
ASC/AGC – – – – – 15 2 3 0 6 13 4 3 0 6
LSIL – – – – – 5 0 0 0 1 4 0 1 0 1
HSIL – – – – – 0 0 0 0 0 0 0 0 0 0
Missing – – – – – 36 1 1 2 129 97 5 2 0 64
ICC ¼ 0.135 ICC ¼ 0.279
Third visit
Negative – – – – – – – – – – 153 9 3 1 47
ASC/AGC – – – – – – – – – – 6 1 1 0 6
LSIL – – – – – – – – – – 2 3 0 0 1
HSIL – – – – – – – – – – 1 0 0 0 1
Missing – – – – – – – – – – 111 7 2 1 47
ICC ¼ 0.179
Neg., negative (normal); Miss., missing (not attending) that specific follow-up visit; ICC, intra-class correlation coefficient (agreement); ASC, atypical squamous cells; LSSL, low-grade squamous
intraepithelial lesions; HSIL, high-grade squamous intraepithelial lesions
One patient treated with hysterectomy and excluded from follow-up
Figure 2 Cumulative incidence of cytological abnormalities during 36 months of follow-up in Kaplan-Meier and log-rank analysis. Baseline
hrHPV-positive women are depicted with a dotted line. Note: different scales for the Y (probability) axis were used in each plot
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epidemiological factors linked to HPV infection. This was not
the main focus of this study, however, but instead we
wanted to assess the accumulation of cytological abnormal-
ities during the follow-up of baseline hrHPVþ and hrHPV2
women. As shown by the significant results, the sample size
was clearly large enough for this specific purpose.
Indeed, testing hrHPV positive at baseline significantly
increased the probability of contracting incident Pap smear
abnormality during the 50 months of prospective follow-up
(Table 1). This was true for all cytological cut-offs used, i.e.
ASC-US, LSIL and HSIL, all of which were significantly
more frequent among baseline hrHPVþ women
(Figure 1). As shown by the survival curves in Figure 1, all
degrees of cytological abnormalities start accumulating
after the first 24 months of prospective follow-up and
continue to do so until the end of the 50-month observation
period. A similar trend has been demonstrated in
several ongoing or concluded cohort studies in Europe as
well.22–24 In the HART (HPV in Addition to Routine
Testing) study, the proposed strategy of reserving cytology
exclusively to triage women with positive HPV tests has
been severely challenged by the high frequency of low-grade
smears among HPVþ women.22 Interestingly, this happened
even though they included only women aged 30–60 years,
attempting to exclude most of the low-grade abnormalities
due to transient hrHPV2 and harmless low-risk HPV infec-
tions.22 It should be noted that the cytological terminology
used in the HART study was not compliant with the
Bethesda system.22 Another major difference between the
HART and LAMS studies is in the living standards of the eli-
gible women, the former also having a significantly better
access to organized screening programmes. The same is
true also for the 7932 women included in the French
cohort.23
It should be also emphasized that cervical cancer,
although an important public health concern in many
European countries, is only the 10th most common cause
of cancer deaths among women in that continent.18 This is
a major deviation from the epidemiological characteristics
of the population from which the LAMS study cohort was
enrolled.10,11 These major differences preclude the general-
ization of the results obtained from the European trials on
HPV testing as a screening tool, for three important
reasons: (1) prevalence of specific HPV types may differ;
(2) behavioural and epidemiological patterns (including
different exposure to HPV, viral loads at sexual intercourse,
concurrent gynaecological infections) may be more risky
among women living in low socioeconomic conditions.
These in turn could facilitate the acquisition and persistence
of hrHPV infections and therefore shortening the ‘protected
period’ between two rounds of HPV screening; (3) most
European trials, with randomized assignment of women to
different screening strategies, are currently underway,
leaving several questions still open.6 All these inherently
divergent geographic and other unsolved issues emphasize
the necessity of a large population-based study in Latin
American continent, capable of evaluating the feasibility of
HPV-based screening in an appropriate setting.
The present data implicate that in addition to the baseline
hrHPVþ women, also women who acquired hrHPV infec-
tion during the follow-up were at significantly increased
risk (HR ¼ 3.5, 95%CI 1.1–11.7) of contracting incident
Pap smear abnormalities. Similarly, women who tested
hrHPVþ at baseline but who cleared their infection, still
held their elevated risk of incident Pap smear abnormalities.
Such patients were quite few, however, compromising the
power of the analysis. On the other hand, most of the Pap
abnormalities found in women with incident hrHPV infec-
tions were low-grade (data not shown in Tables). This is
consistent with the known dynamics of HPV infections and
their related lesions, where HPV infection always precedes
the development of abnormal Pap by several months.25
Because of these temporal relationships, Pap smear abnorm-
alities associated with these newly developed hrHPV infec-
tions are of lower grade as compared with those who had
hrHPV at baseline. However, similar type of results have
been reported in those cohort studies conducted in countries
with high standards of living and high-resource primary
health care.22–24,26–29 This is another argument in favour
of the concept that extending the screening interval of
HPV 2/Pap2 women is safe; even if they contract an inci-
dent hrHPV, the Pap smear abnormality to be detected in
the next screening round (e.g. after three years) is likely to
be of low-grade only.
Another debated issue in the literature is the type of HPV
testing that should be optimal for screening, the response
Table4 Risk estimates for incident cytological abnormalities (atypical squamous cells, low-grade squamous intraepithelial lesions
and high-grade squamous intraepithelial lesions) during follow-up
HR (95% CI)
Characteristic Whole cohort n ¼ 470
Women with positive baseline
hrHPV n ¼ 324
Women with negative baseline
hrHPV n ¼ 146
Positive baseline
hrHPV
3.4 (1.8–6.4) n ¼ 324 (68.9%) – –
Age  30 years 0.8 (0.5–1.3) n ¼ 198 (42.1%) 0.8 (0.5–1.3) n ¼ 141 (43.5%) 1.0 (0.2–4.2) n ¼ 57 (39.6%)
Age at first sexual
intercourse ,18
years
1.9 (1.2–3.0) n ¼ 247 (52.5%) 1.6 (1.0–2.6) n ¼ 181 (55.8%) 3.0 (0.7–12.6) n ¼ 66 (45.2%)
Life time partners 2 0.8 (0.5–1.3) n ¼ 308 (65.5%) 0.7 (0.5–1.3) n ¼ 234 (72.2%) 0.7 (0.2–3.2) n ¼ 74 (50.7%)
Oral hormonal
contraception
1.3 (0.8–2.1) n ¼ 186 (39.6%) 1.3 (0.4–1.3) n ¼ 144 (44.6%) 0.8 (0.2–3.4) n ¼ 42 (28.8%)
Smoking† 0.9 (0.5–1.5) n ¼ 113 (24.0%) 0.7 (0.4–1.4) n ¼ 76 (23.4) (2.0 (0.6–7.8) n ¼ 37 (25.3%)
Persistent HPV during
follow-up‡
– 1.5 (0.9–2.5) n ¼ 103 (31.7%) –
Incident HPV during
follow-up‡
– – 3.5 (1.1–11.7) n ¼ 9 (6.1%)
HR, high risk; HrHPV, high-risk HPV
Reference, other non-hormonal contraception methods
†Reference, women that had NEVER smoked
‡Compared with women with negative HPV tests in ALL follow-up consultations
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still pending.30,31 This is due to multiple reasons, not the
least due to the fact that HPV testing technology is still evol-
ving. HC2 (Digene Corp, Gaithersburg, MD, USA) was the
option found at the time of study design to be the most suit-
able for the detection of hrHPV infections in this series.
Being cost-effective, easy to collect and fairly reproducible,
the technique had the approval for clinical use by the US
Food and Drug Administration and its Brazilian counterpart
(Ageˆncia Nacional de Vigilaˆncia Sanita´ria; ANVISA). The
major limitation of this technique is the failure to identify
the specific HPV types, which would be highly advantageous
in this type of study. Because one of the main aims of this
study was to compare the validity of HPV testing in
Brazilian and Argentinian women, likely to show different
patterns of HPV exposure as compared with the European
and North-American women studied in the published
reports,9,12,13,21 the distribution of HPV genotypes in the
infected women would be useful.
Prophylactic HPV vaccines are emerging as an appealing
strategy for the primary prevention of cervical cancer. Two
vaccines are already available; both having as their primary
target the hrHPV types 16 and 18.32 These two HPV types
were responsible for 50% and 20% of cervical cancer
cases, respectively, in large population-based surveys.33 In
the HPV vaccine era, it is likely that further attention will
be focused on HPV testing, because efficacy of the vaccines
seems to be conditioned by the HPV status of the women.34
Taken together, the present study provides firm evidence
first time also in low-resource settings, suggesting that
hrHPV infection (both baseline and incident) is a significant
risk factor for incident Pap smear abnormalities within a
relatively short follow-up time. Until now, such data were
available only in cohort studies performed in developed
countries with completely different disease burden and
resources for organized cervical cancer screening. This impli-
cates that HPV testing for hrHPV types might be a safe
enough approach to be linked with extension of the screen-
ing interval of hrHPV 2/Pap2 women. Even if some of
them will inevitably contract an incident hrHPV, the process
to develop high-grade cytological abnormality will be long
enough to enable detection of this incident abnormal Pap
at the next screening round (e.g. after three years), most
likely still at the stage of low-grade. This information
should have important implications in planning alternative
screening strategies particularly in the developing countries,
where all resources for public health care are strictly limited.
. . . . . . . . . . . . . . .
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